Novavax (NVAX) Interest Expenses (2010 - 2026)

Novavax's Interest Expenses history runs 17 years deep, the most recent figure standing at $6.3 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 9.98% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $20.5 million (down 71.25% YoY), while the FY2025 annual figure was $1.0 billion, down 9.67% from the prior year.
• Interest Expenses for Q1 2026 stood at $6.3 million, up from $2.9 million in the prior quarter.
• The five-year high for Interest Expenses was $89.5 million in Q4 2023, with the low at $2.9 million in Q3 2023.
• The 5-year median for Interest Expenses is $5.5 million (2025), against an average of $13.0 million.
• The sharpest annual moves came in 2023 and 2025: Interest Expenses soared 1846.23% in 2023, then plunged 94.86% in 2025.
• Novavax's Interest Expenses stood at $4.6 million in 2022, then jumped by 1846.23% to $89.5 million in 2023, then tumbled by 36.24% to $57.1 million in 2024, then slumped by 94.86% to $2.9 million in 2025, then jumped by 114.52% to $6.3 million in 2026.
• Business Quant data shows NVAX's Interest Expenses at $6.3 million in Q1 2026, $2.9 million in Q4 2025, and $7.6 million in Q3 2025.